Plus Therapeutics is a leading cancer radiotherapeutics brand based in Austin, Texas. With a focus on power and precision, they are revolutionizing cancer treatment by delivering targeted radiotherapeutics to tumors while minimizing damage to surrounding healthy tissue. Their innovative approach combines novel drug formulations with advanced administration techniques to insert a single, safe, and effective radiation dose directly into the tumor or affected tissue.

This approach has the potential to preserve normal cell and tissue functioning and improve the quality of life for patients. Plus Therapeutics' radiotherapeutic platform consists of four key components: Rhenium, which emits beta and gamma rays for precise tumor targeting and live imaging; proprietary techniques for transporting and trapping Rhenium into nanoliposomes using a lipophilic chelator (BMEDA); nanoliposomes, which safely encapsulate and deliver radiation to a specific injection site; and biodegradable, embolic, alginate microspheres loaded with radiolabeled nanoliposomes for a novel delivery system. The brand offers two cutting-edge therapies: rhenium (186Re) obisbemeda for brain and central nervous system cancers, and Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM) for solid organ cancers, including liver cancer and metastatic colorectal cancer.

Plus Therapeutics is dedicated to advancing cancer treatment and providing hope for patients and their families